Ontology highlight
ABSTRACT:
SUBMITTER: Kumar SK
PROVIDER: S-EPMC4296007 | biostudies-literature | 2015 Jan
REPOSITORIES: biostudies-literature
Kumar Shaji K SK LaPlant Betsy B Chng Wee Joo WJ Zonder Jeffrey J Callander Natalie N Fonseca Rafael R Fruth Briant B Roy Vivek V Erlichman Charles C Stewart A Keith AK
Blood 20141113 3
Dysregulation of cyclin-dependent kinases is a hallmark of myeloma, and specifically, cdk5 inhibition can enhance the activity of proteasome inhibitors in vitro. Dinaciclib is a novel potent small molecule inhibitor of cyclin-dependent kinases (CDK)1, CDK2, CDK5, and CDK9. Patients with relapsed multiple myeloma and ≤5 prior lines of therapy, with measurable disease, were enrolled. Dinaciclib was administered on day 1 of a 21-day cycle at doses of 30 to 50 mg/m(2). Overall, 27 evaluable patients ...[more]